Mirae Asset Global ETFs Holdings
CTMX icon

Mirae Asset Global ETFs Holdings’s CytomX Therapeutics CTMX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402K Buy
107,334
+90,651
+543% +$346K ﹤0.01% 2108
2026
Q1 		$73.6K Buy
16,683
+724
+5% +$3.67K ﹤0.01% 2806
2025
Q4 		$66.4K Buy
+15,959
New +$60.6K ﹤0.01% 2848

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CTMX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its CytomX Therapeutics (CTMX) stake by 543% in Q2 2026, buying an estimated $346K and bringing the position to 107,334 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #2108.

Mirae Asset Global ETFs Holdings first reported a position in CTMX in Q4 2025 and has held it in 3 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 107,334 shares of CytomX Therapeutics worth $402K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 90,651 CytomX Therapeutics shares in Q2 2026, an estimated $346K.
  • CytomX Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2108 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.